Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

Serhat Sekmek, Irfan Karahan,Gokhan Ucar,Furkan Ceylan,Dogan Bayram, Ismet Seven, Hatice Bölek,Yüksel Ürün,Kadriye Bir Yücel,Ozan Yazici, Ahmet Kadioglu,Cengiz Karacin,Kubra Canaslan,Elif Atag, Serhat Demirer,Gokmen Umut Erdem,Yakup Ergun, Mehmetcan Atak, Baris Koksal,Merve Meryem Kiran, Duriye Ozer Turkay,Burak Civelek,Bulent Yalcin,Dogan Uncu

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico（2024）

引用 0|浏览2

暂无评分

摘要

HER2-positive metastatic gastric cancer is still a highly fatal disease despite advances. We aimed to investigate the relationship between HER2/CEP17 ratio and survival in patients with HER2-positive metastatic gastric cancer. A total of 99 patients from 8 different centers in Turkey were included in the study. Patients with HER2-positive metastatic gastric cancer and whose HER2/CEP17 ratio was examined were included in the study. Patients were divided into two groups according to HER2/CEP17 values, and survival analysis was performed. The median age was 64 (24–83) years. There were 74 (74.8

查看译文

关键词

Gastric cancer,HER2 positive,HER2/CEP17,Survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要